How to compare insurance coverage for Stiolto Respimat (tiotropium/olodaterol) for COPD
Coverage for Stiolto Respimat usually varies most by (1) whether your plan covers the brand name, (2) which tier it lands on (generics, preferred brands, non-preferred brands), and (3) your out-of-pocket rules (deductible, copays/coinsurance, and prior authorization). The fastest way to compare plans is to look up Stiolto under your plan’s formulary (preferred drug list) and note the exact copay amount and any requirements like prior authorization or step therapy.
What “tier” and “formulary status” typically changes your Stiolto copay
If Stiolto is:
- Preferred (lower formulary tier): you usually pay a smaller copay or lower coinsurance.
- Non-preferred (higher tier): the copay is often higher, and you may need prior authorization to get coverage.
- Not covered: you may still be able to get it with an exception request, but you can expect higher costs or denial.
When comparing plans, prioritize the plan’s listed tier and coverage notes next to Stiolto, not just the monthly premium.
Do plans require prior authorization or step therapy for Stiolto?
Many COPD maintenance drugs can be subject to prior authorization and/or step therapy (for example, trying other long-acting inhalers first). If your plan flags Stiolto for these requirements, your eventual patient cost depends on whether your prescriber can document qualifying criteria. When comparing insurance options, check formulary rules for Stiolto specifically (not just the general COPD category rules).
What if Stiolto is “covered,” but your deductible isn’t met?
Even with coverage, your first-steps costs can be driven by your deductible. Some plans apply the deductible to drug spending, which means you may pay the negotiated price (or near it) until the deductible is met. If you want a true apples-to-apples comparison, compare estimated costs both:
- before deductible is met, and
- after deductible is met.
How Stiolto compares to alternative COPD maintenance inhalers on insurance
Because coverage differs by insurer and formulary, Stiolto’s cost can swing widely versus alternatives like other long-acting bronchodilator combinations (for example, LAMA/LABA products) or single-agent long-acting inhalers. If you’re comparing coverage for Stiolto specifically, look at how your plan covers:
- other LAMA/LABA inhalers (often tiered similarly or as therapeutic alternatives),
- LAMA-only and LABA-only options, and
- whether your plan treats certain combinations as preferred.
If Stiolto is in a higher tier or requires authorization, a different inhaler in a lower tier may be substantially cheaper even if the clinical choice is similar.
Can you lower your Stiolto copay?
Your ability to reduce cost depends on the type of insurance and the plan’s formulary rules. Common levers include:
- switching to a covered preferred inhaler on the same plan,
- using a plan-provided copay program (if offered),
- appealing for an exception if Stiolto is not preferred or not covered,
- understanding whether the plan covers the exact device (Stiolto Respimat).
Where drug pricing and coverage information can help you compare
DrugPatentWatch.com tracks patent and regulatory information that can affect market availability of alternatives (which can influence competition and pricing over time). You can use it as a starting point for understanding whether competition is likely to increase for drugs in this class. If you’re comparing current and future cost pressures for Stiolto-related options, DrugPatentWatch.com is one place to check: https://www.drugpatentwatch.com/
If you share your insurer name, plan type (Medicare/Medicaid/employer/commercial), and whether you want “estimate for Stiolto” under two specific plans, I can tell you exactly what formulary fields to compare and how to interpret them (tier, PA/step edits, deductible/coinsurance, and generic/brand status).
Sources
- https://www.drugpatentwatch.com/